Most Read Articles
Roshini Claire Anthony, 4 days ago

A 300 mg QW or Q2W maintenance dupilumab regimen is less likely to result in worsening of atopic dermatitis (AD) than switching to a Q4W or Q8W regimen, results of the phase III LIBERTY AD SOLO-CONTINUE* trial show.

18 Jan 2020
Poorly differentiated cutaneous squamous cell carcinomas (cSCCs) are likely to be incompletely excised in peripheral and deep planes, despite adherence to the British Association of Dermatology-British Association of Plastic, Reconstructive and Aesthetic Surgery guidelines, reports a recent UK study.
28 Nov 2019
The occurrence and severity of hidradenitis suppurativa (HS) are associated with micronutrient status and obesity, suggesting that weight loss and dietary modifications should be considered in the treatment of HS patients, according to the results of a systematic review and meta-analysis.
27 Nov 2019
Earlier-onset atopic dermatitis in children appears to correlate with stronger persistence over time and worse disease control, a recent study has found.

Tildrakizumab yields durable responses for psoriasis

Audrey Abella
19 Mar 2019

Long-term use of the humanized immunoglobulin G1K monoclonal antibody tildrakizumab generated durable responses in adult patients with moderate-to-severe chronic plaque psoriasis*, according to the results of the 3-year extension phases of reSURFACE 1** and 2*** presented at AAD 2019.

The reSURFACE 1 trial randomized 638 individuals (mean age 47.0 years, 67.6 percent male) to receive tildrakizumab 100 or 200 mg every 12 weeks. Of these, 506 (n=239 and 267 for 100 and 200 mg, respectively) entered the long-term extension phase (up to 192 weeks) upon achieving ≥50 percent improvement in Psoriasis Area and Severity Index score (PASI 50) at base study completion. The efficacy analysis was concluded at week 160 due to a drop in the number of participants. [AAD 2019, abstract 10508]

More than half of 100-mg recipients achieved PASI 75/90 at weeks 64 and 160 (87.8 percent/53.8 percent [week 64] and 84.4 percent/57.6 percent [week 160]). The rates were similar in the 200-mg arm (81.6 percent/52.4 percent [week 64] and 75.4 percent/50.8 percent [week 160]).

At week 160, 62.4 percent and 57.1 percent of patients receiving tildrakizumab 100 and 200 mg, respectively, achieved a Physician’s Global Assessment (PGA) response.

Fourteen percent of participants discontinued treatment at week 160, primarily due to patient withdrawal (5.7 percent), adverse events (AEs; 3.4 percent), and loss to follow-up (2.8 percent).

After almost 5 years of treatment, the cumulative number of patients with AEs of interest was low with both tildrakizumab dosages (<1.6 events/100 patient-years [PY]). Confirmed major adverse cardiovascular events (MACE) and drug-related hypersensitivity AEs occurred at very low rates (≤0.8 events/100 PY).

Similar results were observed in the extension phase of reSURFACE 2 (n=381 and 349 for tildrakizumab 100 and 200 mg, respectively), where a majority of participants achieved PASI 75/90 responses at week 52 (92.3 percent/69.9 percent [100 mg] and 88.7 percent/56.7 percent [200 mg]) and week 148 (89.1 percent/64.4 percent [100 mg] and 88.5 percent/61.7 percent [200 mg]). [AAD 2019, abstract 10510]

At week 148, PGA response was achieved by two-thirds of participants receiving tildrakizumab 100 and 200 mg (65.1 percent and 66.4 percent, respectively).

There was a 15.5-percent discontinuation rate by week 148 primarily due to treatment withdrawal (6.0 percent) followed by AEs (2.3 percent).

AE incidence rates in reSURFACE 2 were similar to reSURFACE 1, with low cumulative numbers of patients with AEs of interest for both 100/200-mg dosages (1.2/1.3 PY for severe infections, 0.3/0.6 for confirmed extended MACE, and 0.3/0.2 for drug-related hypersensitivity reactions).

Taken together, with over 3 years of extension, the PASI and PGA response rates were considered high and durable, noted the researchers. The low AE rates suggest a lack of dose effect on safety events, they added.

 

Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

A 300 mg QW or Q2W maintenance dupilumab regimen is less likely to result in worsening of atopic dermatitis (AD) than switching to a Q4W or Q8W regimen, results of the phase III LIBERTY AD SOLO-CONTINUE* trial show.

18 Jan 2020
Poorly differentiated cutaneous squamous cell carcinomas (cSCCs) are likely to be incompletely excised in peripheral and deep planes, despite adherence to the British Association of Dermatology-British Association of Plastic, Reconstructive and Aesthetic Surgery guidelines, reports a recent UK study.
28 Nov 2019
The occurrence and severity of hidradenitis suppurativa (HS) are associated with micronutrient status and obesity, suggesting that weight loss and dietary modifications should be considered in the treatment of HS patients, according to the results of a systematic review and meta-analysis.
27 Nov 2019
Earlier-onset atopic dermatitis in children appears to correlate with stronger persistence over time and worse disease control, a recent study has found.